NC-6004

DRUG5 trials

Sponsors

Orient Europharma Co., Ltd., NanoCarrier Co., Ltd.

Conditions

Carcinoma, Squamous Cell of Head and NeckHead and Neck NeoplasmsPancreatic NeoplasmsSCCHNSolid Tumors

Phase 1

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

CompletedNCT02240238

NanoCarrier Co., Ltd.Solid Tumors

Start: 2014-05-31End: 2019-05-06Updated: 2025-01-22

Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer

TerminatedNCT02817113

Orient Europharma Co., Ltd.Head and Neck Neoplasms

Start: 2016-06-30End: 2018-09-30Updated: 2021-04-30

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

CompletedNCT03109158

NanoCarrier Co., Ltd.Carcinoma, Squamous Cell of Head and Neck

Start: 2017-03-01End: 2019-03-01Updated: 2019-04-29

Phase 2

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

NanoCarrier Co., Ltd.SCCHN

Start: 2019-07-01End: 2022-04-30Target: 136Updated: 2021-03-17

Phase 3

Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer

CompletedNCT02043288

Orient Europharma Co., Ltd.Pancreatic Neoplasms

Start: 2014-01-31End: 2019-12-31Updated: 2020-04-15

Related Papers

Nanomedicine for Combination Therapy of Cancer

EBioMedicine2015-05-0125 citations